{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T19:19:28Z","timestamp":1787858368673,"version":"build-2784847793"},"reference-count":40,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T00:00:00Z","timestamp":1739404800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"Xiao Zhu from Shanghai Municipal Health Commission Clinical Research Youth Project","award":["20224Y0121"],"award-info":[{"award-number":["20224Y0121"]}]},{"name":"Peize Zhang from Shenzhen Clinical Research Center for Tuberculosis","award":["20210617141509001"],"award-info":[{"award-number":["20210617141509001"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,2]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>To assess the safety of 4-week daily rifapentine-isoniazid regimen in latent tuberculosis for Chinese children, and to provide paediatric-specific evidence for extrapolating adult dosing strategies to children.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>An open-label, prospective, single-arm clinical trial was conducted among eligible patients (aged &amp;lt;10\u2005years old). Rifapentine concentrations and laboratory safety biomarker (total bilirubin) were analysed and used for population pharmacokinetic-toxicity model development. Simulations were performed to compare efficacy and safety of weight-based and flat-dosing strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Once-daily rifapentine treatment was well tolerated: 310 samples (rifapentine n\u200a=\u200a139; total bilirubin n\u200a=\u200a171) from 36 children (age range 0.89\u201310\u2005years) were captured well by a joint one-compartment pharmacokinetic with time-varying clearance and an indirect response model. The model adequately described rifapentine autoinduction, reaching a plateau after 21\u2005days and increasing clearance by 70.4%. Simulation suggested that weight-based dosing may cause underexposure in children under 14.5\u2005kg. A flat-dosing strategy could ensure plasma levels within the therapeutic windows. Rifapentine\u2019s impact on total bilirubin was within a 2-fold range, and the effect subsided within 5\u2005days after discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Our study suggested that a flat-dosing strategy of rifapentine was potentially safe and effective for latent tuberculosis infection treatment in Chinese children aged 1 to 10\u2005years old.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/jac\/dkaf029","type":"journal-article","created":{"date-parts":[[2025,2,13]],"date-time":"2025-02-13T04:44:51Z","timestamp":1739421891000},"page":"1022-1030","source":"Crossref","is-referenced-by-count":9,"title":["Pharmacokinetics and safety of rifapentine in children: dosing for latent tuberculosis infection"],"prefix":"10.1093","volume":"80","author":[{"given":"Weijian","family":"Liu","sequence":"first","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nuo","family":"Xu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen Yao","family":"Mak","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"He","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjuan","family":"Qin","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shuihua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongzhou","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoqiang","family":"Xiang","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3295-619X","authenticated-orcid":false,"given":"Xiao","family":"Zhu","sequence":"additional","affiliation":[{"name":"Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University , Shanghai ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4023-0228","authenticated-orcid":false,"given":"Peize","family":"Zhang","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine & Tuberculosis, The Third People\u2019s Hospital of Shenzhen, National Clinical Research Center for Infectious Disease, Southern University of Science and Technology , Shenzhen ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2025,2,13]]},"reference":[{"key":"2025040208380503400_dkaf029-B1","author":"WHO Guidelines Approved by the Guidelines Review Committee"},{"key":"2025040208380503400_dkaf029-B2","author":"WHO Guidelines Approved by the Guidelines Review Committee"},{"key":"2025040208380503400_dkaf029-B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"2025040208380503400_dkaf029-B4","author":"WHO Guidelines Approved by the Guidelines Review Committee"},{"key":"2025040208380503400_dkaf029-B5","doi-asserted-by":"publisher","first-page":"801","DOI":"10.2147\/DDDT.S434919","article-title":"Model-informed precision dosing of isoniazid: parametric population pharmacokinetics model repository","volume":"18","author":"Ju","year":"2024","journal-title":"Drug Des Devel Ther"},{"key":"2025040208380503400_dkaf029-B6","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1001\/jamapediatrics.2014.3158","article-title":"Treatment for preventing tuberculosis in children and adolescents: a randomized clinical trial of a 3-month, 12-dose regimen of a combination of rifapentine and isoniazid","volume":"169","author":"Villarino","year":"2015","journal-title":"JAMA Pediatr"},{"key":"2025040208380503400_dkaf029-B7","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/S2352-4642(21)00052-3","article-title":"Safety and feasibility of 1 month of daily rifapentine plus isoniazid to prevent tuberculosis in children and adolescents: a prospective cohort study","volume":"5","author":"Malik","year":"2021","journal-title":"Lancet Child Adolesc Health"},{"key":"2025040208380503400_dkaf029-B8","doi-asserted-by":"publisher","first-page":"866","DOI":"10.1164\/rccm.201912-2489OC","article-title":"Rifapentine population pharmacokinetics and dosing recommendations for latent tuberculosis infection","volume":"202","author":"Hibma","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"2025040208380503400_dkaf029-B9","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1093\/jpids\/pit077","article-title":"Rifapentine pharmacokinetics and tolerability in children and adults treated once weekly with rifapentine and isoniazid for latent tuberculosis infection","volume":"3","author":"Weiner","year":"2014","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2025040208380503400_dkaf029-B10","doi-asserted-by":"publisher","first-page":"105822","DOI":"10.1016\/j.ijantimicag.2019.10.003","article-title":"World Health Organization 2018 treatment guidelines for rifampicin-resistant tuberculosis: uncertainty, potential risks and the way forward","volume":"55","author":"Van Deun","year":"2020","journal-title":"Int J Antimicrob Agents"},{"key":"2025040208380503400_dkaf029-B11","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.3760\/cma.j.cn112147-20230809-00062","article-title":"[Expert consensus on off-label use of antituberculosis drugs (2023 update)]","volume":"46","author":"Chinese Society for Tuberculosis, Chinese Medical Association","year":"2023","journal-title":"Zhonghua Jie He He Hu Xi Za Zhi"},{"key":"2025040208380503400_dkaf029-B12","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1001\/jama.281.11.1014","article-title":"Hepatotoxicity associated with isoniazid preventive therapy: a 7-year survey from a public health tuberculosis clinic","volume":"281","author":"Nolan","year":"1999","journal-title":"JAMA"},{"key":"2025040208380503400_dkaf029-B13","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1093\/cid\/ciad246","article-title":"A systematic review and meta-analysis of tuberculous preventative therapy adverse events","volume":"77","author":"Melnychuk","year":"2023","journal-title":"Clin Infect Dis"},{"key":"2025040208380503400_dkaf029-B14","doi-asserted-by":"publisher","first-page":"248","DOI":"10.7326\/M17-0609","article-title":"Treatment of latent tuberculosis infection: an updated network meta-analysis","volume":"167","author":"Zenner","year":"2017","journal-title":"Ann Intern Med"},{"key":"2025040208380503400_dkaf029-B15","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1080\/17512433.2017.1366311","article-title":"Rifampin vs. rifapentine: what is the preferred rifamycin for tuberculosis?","volume":"10","author":"Alfarisi","year":"2017","journal-title":"Expert Rev Clin Pharmacol"},{"key":"2025040208380503400_dkaf029-B16","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1056\/NEJMoa2033400","article-title":"Four-month rifapentine regimens with or without moxifloxacin for tuberculosis","volume":"384","author":"Dorman","year":"2021","journal-title":"N Engl J Med"},{"key":"2025040208380503400_dkaf029-B17","doi-asserted-by":"publisher","first-page":"175","DOI":"10.12793\/tcp.2020.28.e20","article-title":"Bioequivalence data analysis","volume":"28","author":"Park","year":"2020","journal-title":"Transl Clin Pharmacol"},{"key":"2025040208380503400_dkaf029-B18","doi-asserted-by":"publisher","first-page":"1051","DOI":"10.2165\/00003088-200544100-00004","article-title":"Quantification of lean bodyweight","volume":"44","author":"Janmahasatian","year":"2005","journal-title":"Clin Pharmacokinet"},{"key":"2025040208380503400_dkaf029-B19","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1007\/s40262-015-0277-z","article-title":"Prediction of fat-free mass in children","volume":"54","author":"Al-Sallami","year":"2015","journal-title":"Clin Pharmacokinet"},{"key":"2025040208380503400_dkaf029-B20","doi-asserted-by":"publisher","first-page":"737","DOI":"10.1136\/archdischild-2013-303720","article-title":"Understanding dosing: children are small adults, neonates are immature children","volume":"98","author":"Anderson","year":"2013","journal-title":"Arch Dis Child"},{"key":"2025040208380503400_dkaf029-B21","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s40262-018-0667-0","article-title":"Choosing the allometric exponent in covariate model building","volume":"58","author":"Sinha","year":"2019","journal-title":"Clin Pharmacokinet"},{"key":"2025040208380503400_dkaf029-B22","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1111\/bcp.13160","article-title":"Scaling clearance in paediatric pharmacokinetics: all models are wrong, which are useful?","volume":"83","author":"Germovsek","year":"2017","journal-title":"Br J Clin Pharmacol"},{"key":"2025040208380503400_dkaf029-B23","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1002\/psp4.12161","article-title":"Model evaluation of continuous data pharmacometric models: metrics and graphics","volume":"6","author":"Nguyen","year":"2017","journal-title":"CPT Pharmacometrics Syst Pharmacol"},{"key":"2025040208380503400_dkaf029-B24","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","article-title":"Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models","volume":"13","author":"Bergstrand","year":"2011","journal-title":"AAPS J"},{"key":"2025040208380503400_dkaf029-B25","doi-asserted-by":"publisher","first-page":"607","DOI":"10.2165\/00003495-199856040-00008","article-title":"Rifapentine","volume":"56","author":"Jarvis","year":"1998","journal-title":"Drugs"},{"key":"2025040208380503400_dkaf029-B26","doi-asserted-by":"publisher","first-page":"e0238521","DOI":"10.1128\/aac.02385-21","article-title":"Population pharmacokinetic modeling and simulation of rifapentine supports concomitant antiretroviral therapy with efavirenz and non-weight based dosing","volume":"66","author":"Pham","year":"2022","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B27","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1002\/cpt.634","article-title":"Defining the optimal dose of rifapentine for pulmonary tuberculosis: exposure-response relations from two phase II clinical trials","volume":"102","author":"Savic","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"2025040208380503400_dkaf029-B28","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/hep.20081","article-title":"Hy's law","volume":"39","author":"Reuben","year":"2004","journal-title":"Hepatology"},{"key":"2025040208380503400_dkaf029-B29","doi-asserted-by":"publisher","first-page":"4037","DOI":"10.1128\/AAC.00554-08","article-title":"Repeated administration of high-dose intermittent rifapentine reduces rifapentine and moxifloxacin plasma concentrations","volume":"52","author":"Dooley","year":"2008","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B30","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/clpt.2011.323","article-title":"Safety and pharmacokinetics of escalating daily doses of the antituberculosis drug rifapentine in healthy volunteers","volume":"91","author":"Dooley","year":"2012","journal-title":"Clin Pharmacol Ther"},{"key":"2025040208380503400_dkaf029-B31","doi-asserted-by":"publisher","first-page":"3035","DOI":"10.1128\/AAC.01918-13","article-title":"Population pharmacokinetics of rifapentine and desacetyl rifapentine in healthy volunteers: nonlinearities in clearance and bioavailability","volume":"58","author":"Savic","year":"2014","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B32","doi-asserted-by":"publisher","first-page":"4429","DOI":"10.1128\/AAC.49.11.4429-4436.2005","article-title":"Population pharmacokinetics of rifapentine and its primary desacetyl metabolite in South African tuberculosis patients","volume":"49","author":"Langdon","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B33","doi-asserted-by":"publisher","first-page":"e01964-18","DOI":"10.1128\/AAC.01964-18","article-title":"A population pharmacokinetic analysis shows that arylacetamide deacetylase (AADAC) gene polymorphism and HIV infection affect the exposure of rifapentine","volume":"63","author":"Francis","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B34","doi-asserted-by":"publisher","first-page":"3390","DOI":"10.1128\/AAC.00345-10","article-title":"Effects of four different meal types on the population pharmacokinetics of single-dose rifapentine in healthy male volunteers","volume":"54","author":"Zvada","year":"2010","journal-title":"Antimicrob Agents Chemother"},{"key":"2025040208380503400_dkaf029-B35","author":"Chang"},{"key":"2025040208380503400_dkaf029-B36","doi-asserted-by":"publisher","first-page":"725","DOI":"10.1016\/j.ijid.2022.07.040","article-title":"Pharmacokinetics of isoniazid and rifapentine in young pediatric patients with latent tuberculosis infection","volume":"122","author":"Phaisal","year":"2022","journal-title":"Int J Infect Dis"},{"key":"2025040208380503400_dkaf029-B37","doi-asserted-by":"publisher","first-page":"e006092","DOI":"10.1136\/bmjopen-2014-006092","article-title":"Lack of weight recording in patients being administered narrow therapeutic index antibiotics: a prospective cross-sectional study","volume":"5","author":"Charani","year":"2015","journal-title":"BMJ Open"},{"key":"2025040208380503400_dkaf029-B38","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1016\/j.jemermed.2004.04.008","article-title":"Errors in weight estimation in the emergency department: comparing performance by providers and patients","volume":"27","author":"Hall","year":"2004","journal-title":"J Emerg Med"},{"key":"2025040208380503400_dkaf029-B39","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1136\/pgmj.2008.071100","article-title":"Weight assessment in cardiac patients: implications for prescription of low molecular weight heparin","volume":"85","author":"Spicer","year":"2009","journal-title":"Postgrad Med J"},{"key":"2025040208380503400_dkaf029-B40","doi-asserted-by":"publisher","first-page":"e230490","DOI":"10.1001\/jamanetworkopen.2023.0490","article-title":"Multinational analysis of estimated health care costs related to extended-interval fixed dosing of checkpoint inhibitors","volume":"6","author":"Goldstein","year":"2023","journal-title":"JAMA Netw Open"}],"container-title":["Journal of Antimicrobial Chemotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1022\/61865947\/dkaf029.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jac\/article-pdf\/80\/4\/1022\/61865947\/dkaf029.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,2]],"date-time":"2025-04-02T05:21:19Z","timestamp":1743571279000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jac\/article\/80\/4\/1022\/8010938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,13]]},"references-count":40,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2025,2,13]]},"published-print":{"date-parts":[[2025,4,2]]}},"URL":"https:\/\/doi.org\/10.1093\/jac\/dkaf029","relation":{},"ISSN":["0305-7453","1460-2091"],"issn-type":[{"value":"0305-7453","type":"print"},{"value":"1460-2091","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,4]]},"published":{"date-parts":[[2025,2,13]]}}}